论文部分内容阅读
仿Peters剂量递增法用伯氏疟原虫ANKA株及N株对QHS进行了抗药性的研究。经14个月的培育至第58代,QHS im注射“4日抑制性实验”的ED_(50)在RQ/ANKA系及RQ/N系分别为其亲代系的53.4及54.6倍,但经蚊传未获成功。在第40代(I_(50)=25)时,其50%的治愈剂量为其亲代系的5.4倍。停药传代其抗性会逐渐消失。该虫系对青蒿酯钠及蒿甲醚有明显的交叉抗性,其ED_(50)分别为其亲代系的13.1及11.7倍,对伯喹的抗性为2.9倍,对氯喹未见明显交叉抗性。
Replicate Peters dose-escalation method with the P. berghei ANKA strain and N strains of QHS were drug-resistant studies. After 14 months of incubation to passage 58, the ED50 of QHS im injection “4-day inhibitory test” was 53.4 and 54.6 times that of their parental lines in RQ / ANKA and RQ / N lines, respectively, Pass did not succeed. At the 40th generation (I_ (50) = 25), the 50% cure dose was 5.4 times that of its parental line. Stop the passage of their resistance will gradually disappear. The worm had significant cross-resistance to artesunate sodium and artemether with ED_ (50) of 13.1 and 11.7 folds of their parental lines, 2.9 times the resistance of primaquine, and no apparent resistance to chloroquine Cross resistance.